TD Cowen raised the firm’s price target on Alignment Healthcare to $10 from $8 and keeps a Buy rating on the shares. The firm updated their model after theyreported 2Q results. Cowen now incorporated the anticipated Part D changes into 2025 and modestly increase EBITDA estimates in 2024/25.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare price target raised to $7 from $4.50 at Barclays
- Alignment Healthcare sees FY24 revenue $2.61B-$2.64B, consensus $2.52B
- Alignment Healthcare sees Q3 revenue $655M-$665M, consensus $630.25M
- Alignment Healthcare reports Q2 EPS (13c), consensus (14c)
- Better Health Outcomes for Seniors, Improved Access to Care and Reduced Environmental Footprint Are Top Achievements Noted in Alignment Healthcare’s 3rd Annual ESG Report